Coppell Advisory Solutions’s Vigil Neuroscience VIGL Stock Holding History

Coppell Advisory Solutions’s Portfolio VIGL Stock Details VIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-34	Closed	-$5.16K	–	1874
2023 Q3	$5.16K	Sell	34 -2,450	-99%	-$16.9K	﹤0.01%	712
2023 Q2	$399K	Sell	2,484 -814	-25%	-$7.7K	0.11%	132
2023 Q1	$502K	Buy	3,298 +2,998	+999%	+$33.7K	0.16%	126
2022 Q4	$45.6K	Buy	+300	New	+$3.68K	0.02%	340

Other funds holding VIGL

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Coppell Advisory Solutions's VIGL Position: Q4 2023 in Review

Coppell Advisory Solutions sold out of Vigil Neuroscience (VIGL) in Q4 2023, closing a stake of 34 shares — an estimated $5.16K sold.

Coppell Advisory Solutions first reported a position in VIGL in Q4 2022 and held it in 4 quarters. The position peaked at $502K in Q1 2023. 46 funds tracked by Wall St. Rank hold VIGL as of Q4 2023.

Coppell Advisory Solutions reported no remaining Vigil Neuroscience position as of Q4 2023 after selling out during the quarter.
Coppell Advisory Solutions sold 34 Vigil Neuroscience shares in Q4 2023, an estimated $5.16K.
Coppell Advisory Solutions first reported a position in Vigil Neuroscience in Q4 2022 and held it in 4 quarters.
Coppell Advisory Solutions's Vigil Neuroscience position peaked at $502K in Q1 2023.
46 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q4 2023.

Based on Coppell Advisory Solutions's 13F filing for Q4 2023, filed 14 Feb 2024.